In pregnant women, CYP3A activity increases by 100% during the third trimester (T3). Due to logistical and ethical constraints, little is known about the magnitude of CYP3A induction during the first (T1) and second (T2) trimesters. Our laboratory has shown that sandwich-cultured human hepatocytes (SCHH) and HepaRG cells have the potential to predict the magnitude of in vivo induction of CYP3A activity likely to be observed in T1 and T2. Therefore, we incubated SCHH and HepaRG cells with plasma concentrations of various pregnancy-related hormones (PRHs, individually or in combination) observed during T1, T2, or T3 in pregnant women. Then, Based on these data, we conclude that C remains the major inducer of CYP3A activity earlier in gestation. Moreover, we predict that the magnitude of CYP3A induction during T1 and T2 will be similar to that observed during T3 (~100% increase vs. postpartum). This prediction is consistent with the observation of similar increase in T2 and T3 oral clearance of indinavir (a CYP3A cleared drug) vs. postpartum.
DMD # 62984

INTRODUCTION
Despite the general apprehension surrounding the use of drugs during pregnancy, a pregnant woman is frequently prescribed medication to treat a variety of preexisting chronic conditions (e.g. HIV infection, epilepsy, hypertension, solid organ transplantation), acute conditions (e.g. influenza), or pregnancy-related conditions (e.g. nausea, gestational diabetes or hypertension).
If left untreated, these conditions could have deleterious consequences to the mother and/or her fetus. Therefore, it is not surprising that between 2006-2008, about 82% of pregnant women took medication sometime during pregnancy and about 50% took medication during the first trimester (Mitchell et al., 2011) .
Pregnancy is associated with a myriad of physiological changes including hepatic metabolism (Abduljalil et al., 2012) . Amongst these is approximately a 2-fold induction of CYP3A activity during the third trimester (T3), as measured by 1'-OH-midazolam formation clearance (Hebert et al., 2008) . Based on genotyping data and modeling and simulation, we have shown that this induction of CYP3A activity is primarily due to induction of hepatic CYP3A4 activity (Hebert et al., 2008; Ke et al., 2012) . Many drugs routinely prescribed to pregnant women are cleared by CYP3A enzymes, such as protease inhibitors (e.g. ritonavir), antihypertensive drugs (e.g. nifedipine), and hypoglycemics (e.g. glyburide). The magnitude of induction in CYP3A activity observed during T3 can result in subtherapeutic plasma concentrations of drugs such as the HIV drug, indinavir (Unadkat et al., 2007) . Logistical and ethical constraints make it difficult to conduct prospective mechanistic studies in pregnant women using validated CYP3A substrates, especially in 1 st (T1) or 2 nd trimester (T2). As a result, the magnitude of induction of CYP3A activity during T1 orT2 is not known. This lack of information makes it difficult for clinicians to design dosing regimens of CYP3A cleared drugs during T1 or T2. DMD # 62984 The plasma concentrations of several pregnancy-related hormones (PRHs) rise substantially as gestation proceeds (Table 1) . Our laboratory has previously demonstrated that a cocktail of PRHs, (the hormone combination containing cortisol (C), progesterone (P), 17β-estradiol (E 2 ), and placental growth hormone (PGH)/growth hormone (GH); hereafter referred to as the PRH cocktail), at their T3 plasma concentrations observed in pregnant women, induced CYP3A activity in sandwich cultured human hepatocytes (SCHH) to an extent comparable to that observed in vivo during T3. Of all these hormones, cortisol was the most potent inducer of CYP3A activity in SCHH. Additionally, the induction pattern observed in SCHH was replicated in HepaRG cells (Papageorgiou et al., 2013) . Both these in vitro models demonstrated their potential to predict the magnitude of CYP3A induction in early pregnancy. Therefore, we
hypothesized that the magnitude of in vivo hepatic CYP3A induction during T1 and T2 can be quantitatively predicted from studies in SCHH or HepaRG cells exposed to PRHs at plasma concentrations observed in pregnant women (for brevity, referred to as "concentrations" hereafter) during T1 and T2. The studies presented here were conducted in HepaRG and SCHH to examine the temporal relationships between concentrations of PRHs and induction of CYP3A activity over the course of pregnancy, and, based on these data, to predict the magnitude of induction in CYP3A activity during T1 and T2. 100ng/mL in 10% acetonitrile), extracted with 800µL methyl tertiary butyl ether, and then centrifuged at 3000g for 15 min. The organic phase was evaporated under nitrogen. The dried residue was reconstituted and derivatized using dansyl chloride to enhance electrospray ionization following the procedure described previously (Kushnir et al., 2008) .
The above samples were analyzed by LS-MS/MS using an Agilent 1290 Infinity UPLC system coupled to an Agilent 6400Triple Quad mass spectrometer. An Acquity UPLC BEH C 18 Column (1.7 µm, 2.1 mm X 50 mm; Waters Corporation, Milford, MA) was used with the mobile phase consisting of 0.1% acetic acid (v/v) in water (A) or 0.1% acetic acid (v/v) in acetonitrile (B)( total flow rate0.25 mL/min -1 ). For cortisol and progesterone assay, the following linear gradient was used: 80% mobile phase A, 0-0.3min; 80-20%, 0.3-1.5min; 20%, 1.5-2.5min; 20%-80%, 2.5-2.6min; 20%, 2.6-4min. Multiple Reaction Monitoring (MRM) pairs selected for (Papageorgiou et al., 2013) . In brief, the differentiated HepaRG cells were maintained for 72 h in WME supplemented with GlutaMAX-I, ITS, and Pennicillin-Streptomycin. At the end of maintenance period, the medium was removed and cells were treated with control (a cocktail of C, GH, E 2 and P at their unbound concentrations observed in non-pregnant women; hereafter referred to as "CTRL") or various PRHs individually or in combination at unbound, 1X, or 10X T1, T2, or T3 concentrations (Table 1) . Because some of the hormones were depleted, the actual incubation concentrations were adjusted, based on their half-life of depletion ( CYP3A activity in these SCHH was determined as described below. All experiments were performed in triplicate.
Cortisol Concentration-CYP3A activity induction Relationship in SCHH
SCHH (batch Hu1587) in collagen-coated 96 well plates were maintained in DEX free medium for 72 h and then treated with CTRL treatment or various concentrations of cortisol, ranging from T1 unbound concentration to 50X T3 concentrations as described above (concentrations were adjusted, where appropriate, to compensate for depletion). CYP3A activity in these SCHH was determined as described below. CYP3A activity in these SCHH was determined as described below. All treatments were performed in duplicate except for the unbound cortisol concentrations and CTRL treatments (n=3).
CYP3A Activity Assay
This article has not been copyedited and formatted. The final version may differ from this version. At the end of the induction period, induction media were aspirated, HepaRG cells or SCHH were rinsed twice with pre-warmed DPBS (~150 µL) and incubated for 60 min (HepaRG cells) or 20 min (SCHH) with 2µM midazolam dissolved in serum-free WME. Then, an equal volume of ice-cold acetonitrile containing 10 nM 1'-OH-midazolam-d4 (internal standard) was immediately added to the supernatant and assayed by LC-MS/MS as described previously (Shirasaka et al., 2013) .
Statistical and Data Analysis
Data are expressed as mean ± SD values unless otherwise stated. One-way analysis of variance (ANOVA) followed by post hoc tests (Dunnett's test when the PRH treatment groups were compared to the CTRL treatment or Tukey's test when PRH treatment groups were compared with each other) were performed. The E max and EC 50 of induction of CYP3A activity by cortisol was estimated by fitting the simple E max or the sigmoid E max model to the concentration-response data using nonlinear regression (Graphpad Prism 5.0, La Jolla, CA). The baseline value of induction (E 0 ) was fixed to 1. The model with the smaller AIC value was selected (Ludden et al., 1994) .
RESULTS
Hormone depletion when incubated with HepaRG or SCHH
In HepaRG cells, cortisol at the unbound concentration observed in non-pregnant women was depleted with a half-life of ~13 h, while at T3 1X and 10X concentrations, cortisol was not depleted (Table 3 ). In contrast, estradiol and progesterone were more rapidly depleted. To compensate for this depletion, the induction media in all future experiments (including SCHH)
were renewed every 12h and the concentrations of the hormones in the media were adjusted so This article has not been copyedited and formatted. The final version may differ from this version. that the average concentration (AUC/τ) approximated the corresponding average concentrations during pregnancy. GHs depletion was not measured as an assay to measure the depletion of PGH is currently not available.
Induction of CYP3A Activity in HepaRG cells by Cortisol or Cortisol plus other PRHs
A pilot study using T3 unbound, 1X, or 10X concentrations of individual PRHs was conducted.
Except for cortisol, none of the PRHs induced CYP3A activity to a significant extent (Figure 1 ).
Therefore, only cortisol and cortisol containing PRH combinations were included in all subsequent experiments described below (including SCHH).
As observed above, cortisol or cortisol plus other hormones consistently, significantly, but variably induced CYP3A activity at 1X or 10X (but not at the unbound) concentrations, compared with CTRL treatment (Figure 2 ). At 10X concentrations, treatments containing C+E 2 or C+ P induced CYP3A activity greater than C alone ( Figure 2B , D, E). But, this greater induction was not consistently present in treatments containing GHs. Our positive control, 10 µM RIF, significantly induced CYP3A activity (range: 5~19-fold), whereas CYP3A activity in the presence of the vehicle control was not significantly different from CTRL (data now shown).
Gestational-Age Dependent Induction of CYP3A Activity in HepaRG Cells by Cortisol or PRH Cocktail
The magnitude of induction of CYP3A activity was not significantly different across the three trimesters at 1X concentrations of the hormones. At 10X concentrations, significant differences emerged ( Figure 3D ). PRH cocktail resulted in varying temporal patterns in different batches at 10X concentrations. No consistent cortisol or PRH cocktail concentration-dependent induction in CYP3A activity was observed.
This article has not been copyedited and formatted. The final version may differ from this version. 
Induction of CYP3A Activity in SCHH by Cortisol or Cortisol plus other PRHs
Similar to HepaRG cells, cortisol and PRH cocktail consistently, variably and significantly induced CYP3A activity in SCHH at 1X and 10X concentrations (and in 1 out of 3 donors at the unbound concentration, data not shown). In batch Hu1587 alone, treatments containing C+GHs or C+E 2 induced CYP3A activity greater than C alone (Figure 4 , A-E). In all three batches, 10
µM RIF significantly induced CYP3A activity (range: 9~16-fold). CYP3A activity in vehicle control was not significantly different from that observed in CTRL.
Gestational-Age Dependent Induction of CYP3A Activity in SCHH by Cortisol or PRH Cocktail
As in HepaRG cells, at 1X concentrations, induction of CYP3A in SCHH was independent of gestational age. At 10X concentrations, CYP3A induction was similar throughout all three trimesters except, in one batch (Hu1587), CYP3A activity was modestly increased (~30%) by PRH cocktail in T3 vs. earlier trimesters.
Concentration-Dependent Induction of CYP3A activity in SCHH by Cortisol
Cortisol induced CYP3A activity in SCHH (batch Hu1587) in a concentration-dependent manner.
The simple E max model rather than the sigmoid E max model was considered to be the best model for the data based on the AIC value respectively) . At cortisol plasma concentrations spanning from T1 to T3, the induction of CYP3A activity reached a plateau and remained constant.
DISCUSSION
Previously, we have shown that of all the PRHs studied, cortisol was the major inducer of CYP3A activity in HepaRG cells and SCHH at T3 concentrations (Papageorgiou et al., 2013) .
Consistent with these findings, cortisol remained the major inducer in HepaRG cells at T1 or T2
concentrations (Figures 2, 3) . Therefore, all subsequent studies examined the induction of CYP3A activity by cortisol alone or in combination with other PRHs. We chose to use the combination of GH and PGH in our incubations as both are present during pregnancy. The plasma concentration of GH decreases while that of PGH increases as pregnancy proceeds (Fuglsang and Ovesen, 2006) . In addition, these two hormones interact with the same receptor with similar affinity (Baumann et al., 1991) and trigger the same intracellular signaling pathways (Silva et al., 2002) . Since some of the hormones were rapidly depleted when incubated with
HepaRG cells or SCHH, we adjusted the incubation concentrations of the hormones and frequency of change of media to account for this depletion. in general, the induction of CYP3A activity in HepaRG cells at 1X concentrations of cortisol alone was comparable to that when cortisol was combined with other PRH(s) (Figure 2A , C, E).
Of note, at 10X concentrations, induction of CYP3A activity with C+E 2 or C+P was greater than C alone. However, this was not always the case when induction in CYP3A activity by the triple combinations of hormones (e.g. C+GHs+P) or the PRH cocktail was compared with C alone.
Based on these observations and due to our previous data in SCHH on C+GHs demonstrating greater induction of CYP3A activity than C alone (Papageorgiou et al., 2013) , the number of hormonal combination treatments examined in SCHH was reduced. Similar to HepaRG cells, despite interbatch variability, the magnitude of induction of CYP3A activity by dual hormone treatments or PRH cocktail was in general comparable to that by C alone at both 1X and 10X
concentrations. One batch of SCHH (Hu1587) exhibited a modestly greater induction of CYP3A activity by the dual hormone treatments (C+E 2 or C+GHs) compared with C alone at 1X and 10X concentrations. At T1, T2 or T3 10X concentrations, the PRH cocktail induced CYP3A activity greater than C alone.
The pattern of induction observed above is consistent with our previous observations where cortisol alone was the major inducer of CYP3A activity in HepaRG cells or SCHH (Papageorgiou et al., 2013) . This work, together with our previous report, provides strong evidence that cortisol is a major inducer of CYP3A activity throughout pregnancy. Indeed, unequivocal data exist that glucocorticoids induce CYP3A activity in human hepatocytes and in vivo (Watkins et al., 1989; Lu and Li, 2001 ). However, the mechanism(s) by which this (Lehmann et al., 1998; Pascussi et al., 2000) . Aside from glucocorticoid receptor and PXR, multiple lines of evidence suggest that a PXR-independent mechanism(s) may be involved in induction of CYP3A activity (Schuetz et al., 2000; Xie et al., 2000; Zimmermann et al., 2009) . Others have also reported enhanced induction of CYP3A activity by cortisol in the presence of GH (Thangavel et al., 2011) . They attributed this to greater activation and nuclear translocation of transcriptional factors (i.e. HNF-4α and PXR) and enhanced binding of these factors to CYP3A4 regulatory region (Thangavel et al., 2011) . Previous studies have demonstrated that at supraphysiological concentrations estradiol or progesterone activates PXR (Handschin and Meyer, 2003; Mnif et al., 2007) .
However, this does not signify that estradiol, progesterone, or both, induces CYP3A activity at plasma concentrations observed in pregnant women. Indeed, consistent with our data, at these lower plasma concentrations of estradiol or progesterone, these hormones failed to consistently induce CYP3A activity in human hepatocytes (Choi et al., 2013) .
Based upon the above data, we examined the induction of CYP3A activity by cortisol alone or by PRH cocktail at T1, T2, or T3 1X or 10X concentrations in both HepaRG cells and SCHH.
Although the absolute magnitude of CYP3A induction varied between these two in vitro models, the induction of CYP3A activity by1X concentrations of cortisol or PRH cocktail was independent of gestational age (Figures 3 and 5) . In contrast, at 10X concentrations, some significant differences manifested, but these differences were modest.
The plasma concentration of cortisol rises considerably as pregnancy proceeds. Cortisol plasma concentration increases from T1 to T2 by ~2-fold and then remain constant during T3. But this 3B; Figure 5A , 5B). To gain insight into this observation, we determined the relationship between cortisol concentration and induction of CYP3A activity in one batch of SCHH ( Figure   6 ). The results show that at the total cortisol plasma concentration (181.5nM) observed in nonpregnant women (Lindholm and Schultz-Moller, 1973; Maroulis et al., 1976; Kalleinen et al., 2008; Matsuzaka et al., 2013) or in pregnant women during T1, T2, or T3, the CYP3A activity would be predicted to be induced by 45%, 120%, 170%, and 170% respectively. While the predicted induction in CYP3A activity during T1 appears numerically lower than that during T2
or T3, our experimental data show that this difference is not statistically significant (Figures 3 and 5). This is because at 1X cortisol concentrations spanning T1-T3, the induction of CYP3A activity appears to be approaching a plateau. Based on these data, we predict that the magnitude of CYP3A induction during T1 or T2 will be similar to that during T3 (~2-fold). Evidence in the literature supports our predictions. Although not an optimum CYP3A probe, urinary dextromethorphan/3-OH-morphinan ratio remains constant throughout pregnancy (Tracy et al., 2005) . Also, the clearance of CYP3A substrates, indinavir and nifedipine, during T2, is comparable to that observed during T3 (Marin et al., 2007; Cressey et al., 2013) .
In summary, this work, together with our previous report, provides strong evidence that cortisol is the major inducer of CYP3A activity throughout pregnancy in HepaRG cells and SCHH.
Moreover, we predict that the magnitude of induction in CYP3A activity during earlier trimesters will be about 2-fold, similar to that in the third trimester. Although these predictions should is expressed relative to control treatment (CTRL, n=6; unbound plasma concentrations of C+GH+E 2 +P observed in non-pregnant women). Data were analyzed by one-way ANOVA followed by Dunnett's test. *, p<0.05; **, p<0.01; ***, p<0.001 compared with CTRL. Data were analyzed by one-way ANOVA followed by Dunnett's test. *, p<0.05; **, p<0.01; ***, p<0.001 compared with CTRL. §, p<0.05; § §, p<0.01; § § §, p<0.001 compared with SCHH exposed to C alone. This article has not been copyedited and formatted. The final version may differ from this version. Carr et al., 1981; 3. Demey-Ponsart et al., 1982; 4. Jung et al., 2011; 5. Soldin et al., 2005; 6. Caufriez et al. ,1998; 7. Wu et al., 2003; 8. Baumann et al, 1988; 9. Meulenberg et al., 1989 Data represent weighted arithmetic means from the above cited studies.
